PAREXEL Receives CEO CANCER GOLD STANDARD Accreditation
BOSTON, August 13, 2015— PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that the CEO Roundtable on Cancer named PAREXEL a CEO Cancer Gold Standard™ employer. The accreditation recognizes the Company’s extraordinary commitment to the health of its employees and their families.
“At PAREXEL, we have a passion for making a profound difference in the lives of people – especially our employees and their families,” said Josef von Rickenbach, Chairman and CEO, PAREXEL. “We are honored the CEO Roundtable on Cancer named us a Gold Standard employer, recognizing our commitment to the health and well-being of our most important asset: our employees.”
To earn CEO Cancer Gold Standard Accreditation, companies must evaluate their health benefits and corporate culture and take extensive, concrete actions to address cancer in the workplace. PAREXEL established programs to reduce cancer risk, including:
- Prohibiting tobacco use and supporting tobacco cessation efforts
- Promoting physical activity, healthy nutrition and weight management
- Offering a Medical Incentive Program to reduce an employee’s health plan contribution following completion of health and wellness activities
- Providing health insurance options that include detecting cancer at its earliest stages, access to quality care and participation in cancer clinical trials
- Supporting the needs of cancer survivors in the workplace
Mr. Von Rickenbach added, “As an expertise-based business, we work together every day towards our goal of improving the lives of millions of patients. That mission starts from within, by giving our employees the tools and support to fight cancer.”
About The CEO Roundtable on Cancer
The CEO Roundtable on Cancer was founded in 2001, when former President George H.W. Bush challenged a group of executives to “do something bold and venturesome about cancer within your own corporate families.” The CEOs responded by creating and encouraging the widespread adoption of the CEO Cancer Gold Standardwhich calls for organizations to evaluate their health benefits and workplace culture and take extensive, concrete actions in five key areas of health and wellness to address cancer in the workplace. For more information on the CEO Cancer Gold Standard™ and the free web-based accreditation process and support, please visit www.CancerGoldStandard.org.
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of expertise-based contract research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL has offices in 80 locations in 51 countries around the world, and had approximately 18,660 employees in the fourth quarter. For more information about PAREXEL International visit www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates.
This release contains “forward-looking” statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ materially from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from restructurings, including expense savings from the $30 – $45 million restructuring charge disclosed in the press release dated June 23, 2015; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions, and to integrate newly acquired businesses including the acquisitions of ClinIntel Limited and Quantum Solutions India, or enter into new lines of business; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of foreign currency exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2015 as filed with the Securities and Exchange Commission on May 1, 2015, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.